Analysis of clinical characteristics of invasive 1

non-typhoidal Salmonella infections in children: a 5-year 2

dual-center retrospective study 3

4 Chenggang Lu¹, Yongping Xie¹, Yan Li¹, Fangfang Cheng², Lisu Huang¹, Wang

Hua^{1*} 5

- 6 1 Department of Infectious Disease, Zhejiang University School of Medicine Children's
- 7 Hospital, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China
- 8 2 Department of Infectious Disease, Children's Hospital of Soochow University, Suzhou,
- 9 Jiangsu, China
- 10 *huawang01@126.com
- 11 Abstract

12 Objective: To investigate the incidence, microbiological characteristics, clinical 13 manifestations, and antibiotic resistance of invasive non-typhoidal Salmonella (iNTS) 14 infections in children.

15 Methods: A retrospective study was conducted from January 2018 to December 2022 at 16 two large teaching hospitals: Zhejiang University School of Medicine Children's Hospital 17 (ZCH) and Children's Hospital of Soochow University (SCH). Medical records of 18 culture-confirmed iNTS cases were reviewed, and a standardized case report form was 19 used to collect demographic, clinical, and microbiological data. 20 Results: A total of 109 cases of iNTS infection were included, with 40 cases from SCH

21 and 69 cases from ZCH. 71 cases (65.1%) were boys.. Infants under 1 year old accounted

22 NOTFOT hopes with the new sessar shifted by the beases if the beases is the beases is the beases if the beases if the beases is the beases

mainly tumors (55.3%,21/38). The most common sites of infection were the bloodstream
(84.4%) and bones and joints (12.8%). The most common serogroups were B (36.8%) ,C
(44.7%) and D (38.2%). The overall resistance rate of ampicillin was 53.6%, ceftriaxone
resistance rate was 17.8%, and carbapenem resistance rate was 0%. Seasonal trends
indicated higher incidence rates during the summer.

28 Conclusion: iNTS infections in children primarily affect the bloodstream and 29 bones/joints, with a significant proportion of cases in those with underlying medical 30 conditions. Ceftriaxone remains the first-line antibiotic, but increasing resistance highlights 31 the need for vigilant antimicrobial stewardship. Carbapenems can be considered as 32 second-line antibiotics in severe cases. Further studies are needed to understand the 33 molecular characteristics and improve treatment strategies for iNTS infections in pediatric 34 patients.

35 Introduction

36 Salmonella is easily transmitted to the human body through foodborne and direct 37 contact routes, and it is a common pathogen in pediatric gastrointestinal infections. Some 38 cases present with extraintestinal infections, including bacteremia and secondary focal 39 lesions. A systematic review estimated(1)that in 2017, there were 535,000 cases of invasive non-typhoidal salmonella (NTS) disease globally, resulting in 77,500 deaths. 40 41 Megged et. al report that the age characteristics of NTS bloodstream infection show a U-shaped distribution and were more common in children and the elderly(2). The highest 42 43 incidence rate of invasive non-typhoidal salmonella disease was observed in children 44 under the age of 5, reaching 34.3 per 100,000 person-years(1). According to a systematic

45 review and analysis of literature on NTS invasive disease cases before June 2021, the 46 overall pooled case-fatality ratio estimates were as follows: 14.7% in Africa, 14.0% in Asia, 47 9.6% in the Americas, and 9.9% in Europe(3). Data from the provinces of Zhejiang and Henan in China indicate that 20.9% to 43.6% of NTS cases result in invasive infections, 48 49 with 52.8% to 67.9% of these cases being bloodstream infections. Furthermore, more 50 than half of the cases affected children(4). Bloodstream infections without appropriate antibiotic treatment are fatal, and changes in antibiotic resistance spectrum can lead to 51 52 treatment failure and dissemination of infection. To date, there is a lack of comprehensive 53 and in-depth understanding among pediatric clinicians regarding invasive salmonella infections, becoming a clinically significant issue that cannot be ignored. 54

55 Materials and Methods

56 Study Population and Data Collection

57 The study included all subtypes of NTS except for typhoid and paratyphoid strains. 58 Invasive non-typhoidal Salmonella infections (iNTS) were defined as cases where 59 specimens cultured from any normally sterile site were positive. The serogroup of the 60 Salmonella isolates was determined using slide agglutination with antisera, and the 61 isolates were classified into seven serogroups: serogroup A-E and other serogroups. Antimicrobial susceptibility testing was determined using a commercial microdilution 62 method (VITEK COMPACT, BioMerieux, France), and the results were interpreted 63 according to Clinical Laboratory Standards Institute guideline M100-ED32. Susceptibility 64 65 to ampicillin, ceftriaxone, chloramphenicol, imipenem, ciprofloxacin, and 66 trimethoprim/sulfamethoxazole (SMZ) was tested. E. coli ATCC25922 was used for quality

67 control. A retrospective analysis was conducted on iNTS data from the Zhejiang University 68 School of Medicine Children's Hospital (ZCH) and the Children's Hospital of Soochow 69 University (SCH) from January 2018 to December 2022. Medical records of confirmed 70 cases were retrieved, and a standardized case report form was used to collect information 71 on age, gender, underlying medical history, symptoms, laboratory examinations, and 72 antimicrobial susceptibility. The pediatric sequential organ failure assessment (pSOFA) 73 score was evaluated according to the previous literature(5). Meteorological data were 74 obtained from the Zhejiang Government Services Network (www.zjzwfw.gov.cn) and 75 JiangSu Meteorological Administration (js.cma.gov.cn).

76 Statistical Analysis

Non-normal variables were presented as median and interquartile range; and categorical variables were described as frequencies.Differences in continuous variables between the bloodstream infection (BSI) group and non-BSI group, as well as between the age >1 year group and the age \leq 1 year group, were compared using the nonparametric Mann-Whitney U test. Proportions were compared using the χ -squared test. *P* <0.05 was considered statistically significant. All statistical analyses were performed using SPSS statistical 27.0 software (IBM, Armonk, NY, USA).

84 Ethics statement

The study was approved by Medical Ethics Committee of the Zhejiang University School of Medicine Children's Hospital and the Children's Hospital of Soochow University (2024-IRB-0193-P-01). Written assent forms were obtained from all participants, along with written consent forms from their guardians.

89 Results

109 cases of iNTS infection were included in the study, with 40 cases from SCH and 69 90 91 cases from ZCH. Of these, 71 cases (65.1%) were boys. Additionally, there were 33 infants (30.3%) under one year old. 38 cases (34.9%) had underlying diseases, mainly 92 93 tumors (21 cases), including 19 cases of acute leukemia, 1 case of bone tumor, and 1 94 case of optic nerve neuroepithelial tumor. None of the cases were co-infected with HIV. 95 There were 92 cases (84.4%) of bloodstream infection, 7 cases of bone marrow infection, 96 7 cases of joint infection, 2 cases of central nervous system infection, and 1 case of 97 pleural effusion. The median time to positive blood culture was 15.8 hours, and the 98 median length of hospital stay was 12 days. There were three deaths, all from ZCH, two of 99 which were boys with acute lymphoblastic leukemia and Salmonella group D infection, 100 and one was a girl with acute monocytic leukemia and Salmonella group B infection. They 101 had significantly elevated pSOFA scores. All three cases had decreased platelet counts and significantly elevated CRP levels. 102

In terms of monthly case numbers and temperature, the curve trends suggest a clear
correlation between temperature and the number of cases in both children's hospitals,
which increasing markedly in summer when temperatures are high. while the correlation
with relative humidity is not obvious. (Fig.1)





107

108 Compared to the BSI group, the non-BSI group had a significantly higher incidence of 109 bone and joint symptoms (52.9% vs. 4.3%, P < 0.001), higher white blood cell count[7.9×10⁹/L vs. 11.1×10⁹/L, P=0.009], higher platelet count [226.5×10⁹/L vs. 110 414.0×10⁹/L, P < 0.001], and longer duration of effective antibiotic use (9.0days vs. 111 25.0days, P < 0.001). There were no significant differences in other indicators. (Tables 1) 112 113 Compared to children over 1 year old, infants aged 1 year or less with iNTS infection 114 had a higher proportion of serogroups B strains(42.4% vs. 18.4%, P = 0.008), a lower 115 proportion of serogroups D strains (12.1% vs. 32.9%, P = 0.024), a higher prevalence of gastrointestinal symptoms (57.6% vs. 26.3%, P = 0.002), a lower proportion of 116 117 hematological system involvement (0% vs. 25.0%, P = 0.002), a lower proportion of 118 underlying diseases (21.2% vs. 40.8%, P = 0.049), a lower proportion of tumor (0% vs. 27.6%, P = 0.001), a lower proportion of deep venous catheterization (3.0% vs. 30.3%, P 119 120 = 0.002). There were no significant differences in other parameters. (Tables 1)

					o /=					•	a /=	
Variables	n	BSI	n	Non-BSI iNTS	χ2/Z	<u>Р</u>	n	Age >1 year	n	Age ≤ 1 year	χ2/Z	P
Demographic												
Boys, n (%)	92	59(64.1)	17	12(70.6)	0.264	0.608	76	50(65.8)	33	21(63.6)	0.047	0.828
Age, months, median (IQR)	92	19.5(12.0,56.3)	17	17.0(10.1,23.0)	-1.374	0.169	/	/	/	/	/	/
Underlying diseases, n (%)	92	34(37.0)	17	4(23.5)	1.139	0.286	76	31(40.8)	33	7(21.2)	3.883	0.049
Tumors, n (%)	92	20(21.7)	17	1(5.9)	1.412	0.235	76	21(27.6)	33	0(0)	11.294	0.001
Deep vein catheter, n (%) 92		23(25.0)	17	1(5.9)	2.042	0.153	76	23(30.3)	33	1(3.0)	9.938	0.002
Laboratory examinations												
WBC, × 10 ⁹ /L, median (IQR)	92	7.9(4.3,11.7)	17	11.1(8.9,13.9)	-2.622	0.009	76	7.6(3.8,11.1)	33	10.4(7.5,15.2)	-3.242	0.001
CRP, mg/L, median (IQR)	92	17.4(5.8,34.3)	17	11.5(4.4,56.3)	-0.167	0.867	76	13.1(2.5,32.6)	33	22.6(7.3,45.2)	-1.636	0.102
PCT, ng/mL, median (IQR)	73	0.3(0.2,0.5)	9	0.2(0.1,10.5)	-0.334	0.739	60	0.3(0.2,0.5)	22	0.4(0.2,0.8)	-1.136	0.256
	00		47		4 004	<	70		00		4 0 0 7	<
Pit, × 10%L, median (IQR)	92	226.5(109.0,306.0)	17	414.0(266.0,565.5)	-4.021	0.001	76	212.5(64.0,298.3)	33	311.0(253.5,380.5)	-4.327	0.001
ALT, U/L, median (IQR)	92	30.0(16.3,62.6)	17	23.0(15.0,34.5)	-1.282	0.200	76	26.2(16.0,55.8)	33	27.0(19.6,57.2)	-0.571	0.568
AST, U/L, median (IQR)	92	48.2(36.0,81.1)	17	38.0(30.5,52.5)	-1.716	0.086	76	47.0(33.2,69.8)	33	48.6(36.0,92.4)	-0.966	0.334
Total bilirubin, umol/L,	01	5 4(2 6 10 5)	16	5 1/2 7 9 2)	0 125	0 000	74	5 7/4 0 10 7)	22	4 1/2 0 6 9)	1 006	0.050
median (IQR)	91	5.4(5.0,10.5)	10	5.1(5.7,6.5)	-0.135	0.092	74	5.7(4.0,10.7)	33	4.1(3.0,0.0)	-1.000	0.059
Serum creatinine, umol/L,	02	27 5/21 0 20 5)	17	24 0(17 0 26 0)	1 000	0.276	76	20 0/21 0 27 7)	22	22 6/20 2 20 5)	1 020	0 202
median (IQR)	92	27.5(21.0,59.5)	17	24.0(17.0,30.0)	-1.090	0.270	70	29.0(21.0,37.7)	33	23.0(20.2,39.3)	-1.029	0.303
Blood lactate, mmol/L,	01	2.0(1.7, 2.0)	17	20(1 = 2 = 1)	0.050	0 220	75	24(1720)	22	24/1720	0 479	0.622
91 median (IQR)		2.2(1.7,2.9)	17	2.0(1.5,2.5)	-0.959	0.338	75	2.1(1.7,2.9)	33	2.4(1.7,3.0)	-0.478	0.633
Serogroup, n (%)												
В		24(26.1)		4(24.5)	0.000	1.000		14(18.4)		14(42.4)	6.945	0.008
С	92	26(28.3)	17	8(47.1)	2.362	0.124	76	25(32.9)	33	9(27.3)	0.339	0.560
D		27(29.3)		2(11.8)	1.461	0.227		25(32.9)		4(12.1)	5.085	0.024

Table 1. Demographic and clinical manifestations of children with iNTS infections, 2018–2022.

E	8(8.7)		0(0)	0.573	0.449		5(6.6)		3(9.1)	0.004	0.950	
non A-E 7(7.6)		3(17.6)	0.740	0.390	7(9.2)			3(9.1)	0.000	1.000		
Source of infection												
BSI, n (%)	/	/	/	1	/	/		66		26	1 12/	0.287
Non-BSI, n (%)	/	/	/	/	/	/		10		7	1.134	0.207
Clinical presentations, n (%)												
Fever		69(75.0)		10(58.8)	1.882	0.170		52(68.4)		27(81.8)	2.070	0.150
Gastrointestinal symptoms		35(38.0)		4(23.5)	1.315	0.251		20(26.3)		19(57.6)	9.785	0.002
Cough		7(7.6)		2(11.8)	0.327	0.567		6(7.9)		3(9.1)	0.043	0.835
Hematological symptoms	92	18(19.6)	17	1(5.9)	1.866	0.172	76	19(25.0)	33	0(0)	9.992	0.002
Bone and joint		4(4.3)		9(52.9)	32.255	< 0.001		10(13.2)		3(9.1)	0.362	0.547
Others		7(7.6)		2(11.8)	0.009	0.926		6(7.9)		3(9.1)	0.000	1.000
pSOFA≥2, n (%)	92	50(54.3)	17	5(29.4)	3.569	0.059	76	34(44.7)	33	20(60.6)	2.318	0.128
Outcomes												
Duration of effective antibiotic	00	0.0/7.0.40.0)	47		4 004	<	70	40.0/7.0.42.0)	22	0.0/0.5.42.0)	0.754	0 454
use, days, median (IQR)	92	9.0(7.0,12.0)	17	25.0(11.5,42.0)	-4.091	0.001	76	10.0(7.0,13.8)	33	9.0(6.5,13.0)	-0.754	0.451
Length of hospital stay, days,	02	10.0(0.0.17.9)	17	17 0(10 0 52 0)	1 0 4 5	0.050	76	10.0(0.0.00 E)	22	12 0/9 E 17 0)	0 400	0.670
median (IQR)	92	12.0(9.0,17.0)	17	17.0(10.0,53.0)	-1.945	0.052	70	12.0(9.0,20.5)	33	13.0(0.5,17.0)	-0.423	0.072
Time to positive blood	02	15 8(13 0 21 2)	17	16 9/9 / /6 5)	0 350	0 710	76	15 7/10 6 01 2\	22	16 4/12 2 25 0)	0 155	0 977
culture, hours, median (IQR)	92	13.0(13.0,21.2)	17	10.0(0.4,40.3)	-0.559	0.719	70	13.7(12.0,21.3)	33	10.4(12.3,23.9)	-0.155	0.077
Death, n (%)	92	3(3.3)	17	0(0)	0.570	0.450	76	3(3.9)	33	0(0)	1.339	0.247

122	In the strain serogroups, there were 28 cases (36.8%) in serogroup B, 34 cases (44.7%)
123	in serogroup C, 29 cases (38.2%) in serogroup D, 8 cases in serogroup E, and 10 cases
124	in non-A-E serogroup. The overall resistance rate of ampicillin was 53.6% (45/84),
125	ceftriaxone resistance rate was 17.8% (19/107), SMZ resistance rate was 27.1% (29/107),
126	ciprofloxacin insensitivity rate was 35.3% (30/85), chloramphenicol resistance rate was
127	35.6% (16/45), and carbapenem resistance rate was 0%. There were significant
128	differences in the resistance of ampicillin, ceftriaxone, SMZ, and chloramphenicol among
129	different NTS serogroups, while there was no significant difference in ciprofloxacin
130	insensitivity rate. (Table 2)

Table 2. Antibiotic resistance of different Serogroups of NTS to six antibiotics

Antibiotic	Serogroup B	Serogroup C	Serogroup D	Serogroup E	Serogroup non A-E	χ2	Ρ
Ampicillin	12/21(57.1%)	9/29(31.0%)	19/25(76.0%)	3/3(100%)	2/6(33.3%)	16.222	0.003
Ceftriaxone	8/28(28.6%)	2/33(6.1%)	4/28(14.3%)	5/8(62.5%)	0/10(0%)	17.941	0.001
SMZ	15/28(53.6%)	6/33(18.2%)	2/28(7.1%)	5/8(62.5%)	1/10(10.0%)	23.573	<0.001
Ciprofloxacin	11/21(52.4%)	7/29(24.1%)	9/26(34.6%)	1/3(33.3%)	2/6(33.3%)	4.254	0.373
Chloramphenicol	9/11(81.8%)	4/16(25.0%)	2/15(13.3%)	1/1(100%)	0/2(0%)	18.368	0.001
Carbapenems	0/20(0%)	0/17(0%)	0/17(0%)	0/8(0%)	0/7(0%)	/	/

131 Discussion

132 Among the 109 cases of iNTS, nearly 2/3 (65.1%) were boys, 38 cases had underlying diseases, and nearly half had acute lymphoblastic leukemia. The three death cases all 133 134 came from bloodstream infection in children with hematological tumors after chemotherapy. The pSOFA score increased significantly. Due to the small number of 135 136 death cases, statistical analysis of high-risk factors cannot be performed. pSOFA is helpful 137 for disease assessment and prognosis judgment. It should be mentioned that the pSOFA

138 score indicators include serum creatinine and bilirubin, which limits early clinical 139 application(5). Different from the total case fatality rate estimated in global reviews of 140 14.7%(3). there were few deaths in this study. Considering the different underlying 141 disease spectrum, there were no children with HIV, which may also be the reason for the 142 large difference in mortality. We noticed that there were no fatal cases reported in NTS 143 bloodstream infection studies from Malaysia(6), Israel(2), Japan(7), and Taiwan, China(8). The incidence of iNTS in children in both centers is related to temperature. During the 144 145 high temperature season in summer, the number of incidences reaches a peak, while in 146 winter and spring, the number of incidences decreases significantly. Possible factors 147 include rising temperatures, easy reproduction of bacteria, easy deterioration of food, and 148 water pollution, which are all risk factors for increasing NTS infection. Mohan et al. from 149 Malaysia reported that there was no significant correlation between the monthly incidence of iNTS and the average monthly rainfall(9). In Hong Kong, China, it was reported that the 150 151 peak of hospitalization for NTS infection was in June and the trough was in April(10). It 152 shows that different latitudes in different regions are related to the seasonal characteristics of NTS incidence. 153

In this group of studies, the most common were BSI (84.4%) and bone and joint infection (12.8%). The clinical characteristics of the two groups and the antibiotic resistance are basically similar. The non-BSI iNTS group has a younger age of onset and longer antibiotic treatment time, suggesting that the non-BSI iNTS may have experienced a BSI process. Infections caused by blood circulation dissemination, it will take longer to clear the germs that spread the lesions. The higher white blood cell and platelet counts in

160 the non-BSI group suggest a more severe inflammatory response in cases of non-BSI. Clinically, joint infection may spread hematogenously or directly spread from open wounds. 161 162 This data found that the clinical parameters of the BSI group and the non-BSI iNTS group 163 were mostly the same, and the clinical characteristics were similar, suggesting that the 164 invasive infection group without BSI had bloodstream infection in early stage and spread 165 the lesions through the blood circulation. The antibiotic treatment time in the non-BSI iNTS group was 2.5 times longer, indicating that it takes longer to clear bacteria from bone 166 167 marrow, joints, cerebrospinal fluid and other lesions. Two studies in the United States 168 compared the duration of intravenous antibiotic treatment for NTS BSI in children with >3 169 days to ≤ 3 days(11), and compared the duration of < 7 days with ≥ 7 days(12). The clinical 170 outcomes were good, and recommendations with oral antibiotics can be made as soon as 171 possible. However, these two groups of cases were mild children with no invasive infection lesions and no underlying diseases, which were different from the cases studied 172 173 in our groups.

174 Comparing the age groups, it can be found that serogroup B is more common in the 175 infant group and serogroup D is less common. Clinical symptoms such as diarrhea and 176 vomiting are more common. The proportion of older children with underlying diseases (mainly leukemia) and deep vein catheterization is higher than that of infants, indicating 177 178 that with the age increases, acquired immune function strengthens, and the number of 179 iNTS infections among children with normal immune function gradually decreases. The study by Sirinavin et al. from Thailand reported a group of 75 infant iNTS cases, including 180 181 transient bacteremia (5), bacteremia without localized infection (37), bone and joint

infection (5) and meningitis (28); while in our two centers, the cases were primarily
bloodstream infections, only 2 cases of central nervous system infection, indicating a
different spectrum of the disease. This also highlights the importance for clinicians to be
vigilant about intracranial infections in infant iNTS infections(13).

186 NTS from different specimen sources are similar in antibiotic resistance, suggesting that 187 infections at other invasion sites may also be caused by dissemination of BSI. In this study, the serogroups were predominantly B, C, and D, with relatively few serogroups E and 188 189 other groups, which is similar to what was reported by Megged et al(2). In the NTS BSI 190 reported by Lee et al. in Taiwan, serogroup D was the most common(14), their study 191 showed that the ampicillin resistance rate was 53%, the third-generation cephalosporin 192 resistance rate gradually increased to 11%, and the ciprofloxacin resistance rate dropped 193 from 20% to 11%. In this study, ampicillin resistance exceeded 50%, carbapenem 194 resistance was 0%, SMZ resistance was 27%, ceftriaxone resistance was 18%, and 195 ciprofloxacin was mostly intermediate, with a proportion close to 35%. Our data indicate 196 the emergence of extensive resistance to ampicillin, suggesting that Salmonella has 197 extensively produced β -lactamase. Most are sensitive to ceftriaxone, but the resistance 198 rate continues to rise. Some studies have used pulsed field gel electrophoresis to identify Salmonella strains that are resistant to ceftriaxone and identified the blaCMY-2 gene on 199 200 the Incl1 plasmid; through horizontal gene transfer, the MIC of ceftriaxone for the recipient strain increased from 0.125 μ g/mL to 32 μ g/mL(15). The ciprofloxacin resistance rate has 201 202 not declined because there are more intermediaries, which is closely related to the breakpoints defined by the Clinical Laboratory Standards Institute guidelines. Comparing 203

204 the antibiotic resistance of different serogroups, it was found that serogroup E had the 205 highest resistance rate to ampicillin, ceftriaxone, SMZ, and chloramphenicol. The 206 resistance rate of ceftriaxone in serogroup C was 6.1%, while the resistance rate in serogroup E was the highest at 62.5%. To date, Ceftriaxone is still the first-line drug and 207 208 serogroups has a certain guiding role in the selection of antibiotics. It is noteworthy that 209 the drug resistance rate of Salmonella is gradually increasing. Garcia et al. in Peru reported multidrug-resistant Salmonella serovar Infantis (from serogroup C) were only 210 211 sensitive to carbapenems(16). In our study, all carbapenems are sensitive. Considering 212 that children with iNTS are more likely to have underlying diseases and have immune 213 dysfunction, carbapenem antibiotics can be used as second-line antibiotics when severe 214 invasive infections occur.

This study is a retrospective study, and the strains isolated from the specimens are only grouped into serogroups without serotype classification, which limits further analysis of molecular characteristics. Secondly, the specimens of invasive infection are mainly from blood, bone and joint, and there is very little from CSF and pleural effusion, which limits in-depth comparative analysis of clinical characteristics. However, the 109 iNTS cases are still a relatively large cohort and can provide meaningful reference for subsequent research on the clinical characteristics and treatment of Salmonella.

222 Conclusion: The clinical manifestations and treatment of iNTS infection in children are 223 related to the site of invasion. Ceftriaxone is still the first-line antibiotic, but the resistance 224 is gradually increasing. Carbapenems can be considered as second-line antibiotics in 225 severe cases.

226

227

References:

- 228 1. Stanaway JD, Parisi A, Sarkar K, Blacker BF, Reiner RC, Hay SI, et al. The global burden of 229 non-typhoidal salmonella invasive disease : a systematic analysis for the Global Burden of Disease 230 Study 2017. LANCET INFECT DIS. 2019 2019/1/1;19(12):1312-24.
- 231 2. Megged O, Assous M. Non-typhoidal Salmonella bacteremia : comparison of adults and children 232 in a single medical center. J MED MICROBIOL. 2022 2022/1/1;71(5).
- 233 3. Marchello CS, Birkhold M, Crump JA. Complications and mortality of non-typhoidal salmonella 234 invasive disease: a global systematic review and meta-analysis. LANCET INFECT DIS. [Journal 235 Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; 236 Systematic Review]. 2022 2022/5/1;22(5):692-705.
- 237 4. Hu Y, Wang J, Chen S, Li Y, Zhang R, Chen S. Non-typhoidal salmonella invasive infections in 238 China. LANCET INFECT DIS. [Comment; Letter; Research Support, Non-U.S. Gov't]. 2022 239 2022/7/1;22(7):939.
- 240 5. Matics TJ, Sanchez-Pinto LN. Adaptation and Validation of a Pediatric Sequential Organ Failure 241 Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children. JAMA 242 PEDIATR. [Journal Article; Observational Study; Validation Study]. 2017 2017/10/2;171(10):e172352.
- 243 6. Nor AA, Fadzilah MN, Mariam M, Anis SZ, Ariza A, Noor SM, et al. Community-acquired 244 bacteremia in Paediatrics: Epidemiology, aetiology and patterns of antimicrobial resistance in a 245 tertiary care centre, Malaysia. Med J Malaysia. [Journal Article]. 2016 2016/6/1;71(3):117-21.
- 246 7. Aoki Y, Kitazawa K, Kobayashi H, Senda M, Arahata Y, Homma R, et al. Clinical features of 247 children with nontyphoidal Salmonella bacteremia: A single institution survey in rural Japan. PLOS 248 ONE. [Journal Article]. 2017 2017/1/20;12(6):e176990.
- 249 8. Chang Y, Chen Y, Chen N, Hsu Y, Chu H, Chen C, et al. Changing Antimicrobial Resistance and 250 Epidemiology of Non-Typhoidal Salmonella Infection in Taiwanese Children. FRONT MICROBIOL. 251 2021:12.
- 252 9. Mohan A, Munusamy C, Tan Y, Muthuvelu S, Hashim R, Chien S, et al. Invasive Salmonella 253 infections among children in Bintulu, Sarawak, Malaysian Borneo: a 6-year retrospective review. 254 BMC INFECT DIS. 2019;19.
- 255 10. Woh PY, Yeung MPS, Nelson EAS, Goggins WBI. Risk factors of non-typhoidal Salmonella 256 gastroenteritis in hospitalised young children : a case-control study. BMJ PAEDIATR OPEN. 2021 257 2021/1/1;5(1).
- 258 11. Glover B, Charvat C, Weiss L, Kirpalani A, Shane AL, Li R, et al. Intravenous Antibiotic Duration 259 for Nontyphoidal Salmonella Bacteremia in Children. Hosp Pediatr. [Journal Article]. 2022 260 2022/7/1;12(7):e225-9.
- 261 12. Hess LM, Burdick B, Minard CG, Dutta A. IV Antibiotic Durations for Nontyphoidal Salmonella 262 Bacteremia. Hosp Pediatr. [Journal Article; Observational Study]. 2019 2019/12/1;9(12):993-7.
- 263 13. Sirinavin S, Chiemchanya S, Vorachit M. Systemic nontyphoidal Salmonella infection in normal 264 infants in Thailand. PEDIATR INFECT DIS J. [Journal Article]. 2001 2001/6/1;20(6):581-7.
- 265 14. Lee CM, Lee MS, Yang TL, Lee KL, Yen TY, Lu CY, et al. Clinical features and risk factors 266 associated with bacteremia of nontyphoidal salmonellosis in pediatric patients, 2010-2018. J 267 FORMOS MED ASSOC. [Journal Article]. 2021 2021/1/1;120(1 Pt 1):196-203.

15. Yang WC, Chan OW, Wu TL, Chen CL, Su LH, Chiu CH. Development of ceftriaxone resistance
in Salmonella enterica serotype Oranienburg during therapy for bacteremia. J MICROBIOL
IMMUNOL. [Case Reports; Journal Article; Research Support, Non-U.S. Gov't]. 2016
2016/2/1;49(1):41-5.

- 272 16. Garcia C, Hinostroza N, Astocondor L, Ochoa T, Jacobs J, For TSCN. Characterization of
- 273 ESBL-Producing Salmonella enterica Serovar Infantis Infection in Humans, Lima, Peru. AM J TROP
- 274 MED HYG. [Journal Article; Research Support, Non-U.S. Gov't]. 2019 2019/10/1;101(4):746-8.